INT287838

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 18
Disease Relevance 0.64
Pain Relevance 0.29

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Cand1) nucleus (Cand1)
Anatomy Link Frequency
hearts 3
cardiomyocytes 2
Cand1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
adenocard 18 89.60 High High
addiction 54 88.44 High High
agonist 18 80.28 Quite High
lidocaine 90 5.00 Very Low Very Low Very Low
ketamine 18 5.00 Very Low Very Low Very Low
Thoracotomy 18 5.00 Very Low Very Low Very Low
imagery 18 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Targeted Disruption 54 94.72 High High
Coronary Heart Disease 18 82.92 Quite High
Myocardial Infarction 18 81.48 Quite High
Hypertrophic Cardiomyopathy 18 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Since cMyBP-C and cTnI phosphorylation are strongly associated (Fig. 6D), it is not possible from these experiments to distinguish directly between effects of cMyBP-C and cTnI phosphorylation on Ca2+-sensitivity of force development.
Phosphorylation (phosphorylation) of C and
1) Confidence 0.80 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0.09 Pain Relevance 0
Their results at submaximal activation indicate that ablation of murine cardiac cMyBP-C and PKA phosphorylation of cMyBP-C both accelerate the rate of force generation.
Phosphorylation (phosphorylation) of C and
2) Confidence 0.80 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0.07 Pain Relevance 0.08
The correspondence between the cMyBP-C and cTnI phosphorylation levels in the Quiescence hearts perfused with 0.2 mM and 1.36 mM CaCl2 was unexpected.
Phosphorylation (phosphorylation) of C and in hearts
3) Confidence 0.80 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0 Pain Relevance 0.04
Since cMyBP-C and cTnI phosphorylation are strongly associated (Fig. 6D), it is not possible from these experiments to distinguish directly between effects of cMyBP-C and cTnI phosphorylation on Ca2+-sensitivity of force development.
Phosphorylation (phosphorylation) of C and
4) Confidence 0.80 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0.08 Pain Relevance 0
Cardiac MyBP-C and cTnI phosphorylation were markedly increased (3.7-fold) in the Isoprenaline group relative to the Quiescence group (P<0.01).
Phosphorylation (phosphorylation) of C and
5) Confidence 0.80 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0 Pain Relevance 0
Additional evidence to support this notion originates from the observations that the final phosphorylation levels of cMyBP-C and cTnI in the cardiomyocyte suspension after PKA-treatment exceeded the average values in the Quiescence and Contraction group.
Phosphorylation (phosphorylation) of C and in cardiomyocyte
6) Confidence 0.80 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0.15 Pain Relevance 0
The cMyBP-C and cTnI phosphorylation levels in the Quiescence and Contraction group were very similar.
Phosphorylation (phosphorylation) of C and
7) Confidence 0.80 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0.08 Pain Relevance 0
In quiescent Langendorff-perfused hearts MLC-1, MLC-2, cMyBP-C and cTnI were mainly dephosphorylated, indicating that the relevant balance had been shifted in favour of phosphatase activity.
Phosphorylation (dephosphorylated) of C and in hearts
8) Confidence 0.80 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0 Pain Relevance 0.07
Fig. 6A, B Quantitative analysis of cMyBP-C and cTnI phosphorylation from 1D-gels by Pro-Q Diamond and Sypro Ruby staining.
Phosphorylation (phosphorylation) of C and
9) Confidence 0.80 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0 Pain Relevance 0
The increases in cMyBP-C and cTnI phosphorylation are consistent with literature data (e. g. [5]) and can be attributed to the increased activity of PKA but, because of the associated rise in the time-averaged intracellular Ca2+ concentration [2], altered activities of the Ca2+-dependent kinases CaMK II and classical PKC isoforms and, indirectly, of phosphatases such as PP-1 [22] may be involved as well.
Phosphorylation (phosphorylation) of C and
10) Confidence 0.80 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0 Pain Relevance 0
The averaged levels of cMyBP-C and cTnI phosphorylation in the Contraction group were not significantly increased.
Phosphorylation (phosphorylation) of C and
11) Confidence 0.79 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0 Pain Relevance 0.07
These experiments indicate that the PKA-sensitive phosphorylation sites on cMyBP-C and/or cTnI were not saturated under basal conditions even in the Isoprenaline group.
Phosphorylation (phosphorylation) of C and
12) Confidence 0.61 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0.16 Pain Relevance 0
Averaged values (± SEM) values are shown in the Quiescence (Q), Contraction (C) and Isoprenaline (Iso) group. cMyBP-C and cTnI phosphorylation in the Isoprenaline group were significantly increased relative to the Quiescence and Contraction group.
Phosphorylation (phosphorylation) of C and
13) Confidence 0.61 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0 Pain Relevance 0
Comparison of the final levels reached with the corresponding levels in Fig. 6A and B clearly illustrates that cMyBP-C and cTnI phosphorylation was not complete in the Contraction group, while Isoprenaline treatment resulted in phosphorylation levels that were higher than those attained after PKA treatment.
Phosphorylation (phosphorylation) of C and
14) Confidence 0.61 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0 Pain Relevance 0
Addition of Isoprenaline to the electrically paced (5 Hz) heart caused marked elevations of the cMyBP-C and cTnI phosphorylation levels, but did not result in a further significant increase in MLC-2 phosphorylation.
Phosphorylation (phosphorylation) of C and in heart
15) Confidence 0.61 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0 Pain Relevance 0.03
D, E Effect of incubation of tissue from the Quiescence group with the active subunit of protein kinase A. cMyBP-C and cTnI phosphorylation increased with the duration of the incubation and saturated after approximately 30 min.
Phosphorylation (phosphorylation) of C and
16) Confidence 0.61 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0 Pain Relevance 0
This latter finding suggests that Isoprenaline also caused phosphorylation of other sites on cMyBP-C and cTnI, distinct from the PKA-sites (cTnI: Ser23/24; cMyBP-C: S279/288/308).


Phosphorylation (phosphorylation) of C and
17) Confidence 0.61 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0 Pain Relevance 0
To assess the time course and magnitude of PKA-induced phosphorylation of cMyBP-C and cTnI, suspensions of cardiomyocytes from a sample of the Quiescence group, where phosphorylation was low, were incubated with recombinant PKA as described in the Methods.
Phosphorylation (phosphorylation) of C and in cardiomyocytes
18) Confidence 0.61 Published 2007 Journal Basic Res Cardiol Section Body Doc Link PMC2780643 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox